Noxopharm Ltd (ASX:NOX) managing director and CEO Graham Kelly highlights the comapny's investment proposition at Proactive's Lifesciences Webinar on Tuesday, August 10.
Kelly said the key differentiator between Noxopharm and other clinical-stage drug development companies lies in its unique, proprietary technology platform.
He said the platform is capable of multiple assets, including offering a revolutionary concept in the treatment of degenerative diseases such as cancer, chronic inflammatory diseases, and autoimmune diseases.